Particularly, since Epstein-Barr virus (EBV) can cause endemic BL and other immunosuppression-related lymphomas [256], CRISPR genome-wide screens have been parallelly performed in BL and lymphoblastoid cell lines to identify several EBV-driven B-cell synthetic lethal targets for therapeutic intervention, including the evasion of TNFα, BIM, and BLIMP1 effects [257]. The gene discussed is PRDM1; the disease is Burkitt lymphoma.